Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print          Annual reports

Thursday 25 June, 2020

Hikma Pharmaceutical

Directorate Change

RNS Number : 1135R
Hikma Pharmaceuticals Plc
25 June 2020

Jochen Gann Resigns from the Board of Hikma



London, 25 June 2020 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ( Hikma ) announces that, following the disposal of shares by Boehringer Ingelheim Invest GmbH (part of the Boehringer Ingelheim group of companies which includes Boehringer Ingelheim International GmbH and Boehringer Ingelheim Corp. ('BI')) and in accordance with the shareholder agreement between Hikma and BI, that Dr. Jochen Gann has resigned his directorship of Hikma with immediate effect.


Said Darwazah, Executive Chairman , said: 'Jochen Gann has brought a wealth of experience to the Hikma Board.  It has been a pleasure working with Jochen over the last five years and we wish him well for the future.'


-- ENDS --




Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary  +44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs      +44 (0)20 7399 2760


About Hikma


Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:


LEI: 549300BNS685UXH4JI75

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t